Johns Hopkins University School of Medicine, 1830 East Monument Street, Room 435, Baltimore, MD 21287, USA.
Curr Infect Dis Rep. 2009 May;11(3):246-54. doi: 10.1007/s11908-009-0036-0.
The prevalence of HIV in patients over the age of 50 years is increasing. Although older patients may achieve equal or better virologic suppression at equal rates compared with younger patients, the immunologic benefit of highly active antiretroviral therapy (HAART) in older patients may be reduced compared with younger patients. Comorbidities are more common in older patients than younger patients and can impact management of HIV in these patients. Providers must be cognizant of drug-drug interactions and side effects of HAART regimens when selecting an antiretroviral regimen in older HIV patients. As the HIV-infected population ages, there is a growing need to better determine the ideal HAART regimen and timing of HAART initiation in older patients.
50 岁以上患者中 HIV 的流行率正在上升。尽管与年轻患者相比,老年患者可能以相同的速度或更高的速度达到相等或更好的病毒学抑制,但与年轻患者相比,高效抗逆转录病毒治疗(HAART)在老年患者中的免疫获益可能会降低。与年轻患者相比,老年患者的合并症更为常见,这可能会影响对这些患者的 HIV 管理。在为老年 HIV 患者选择抗逆转录病毒方案时,提供者必须认识到药物相互作用和 HAART 方案的副作用。随着 HIV 感染人群的老龄化,越来越需要更好地确定老年患者的理想 HAART 方案和 HAART 启动时机。